The European Pharmacopoeia Committee of Chinese Medicine Committee Gerhard Franz said at the International Summit of Chinese Medicine in Hangzhou on the 29th that as of May 2016, 66 kinds of Chinese herbal medicines have entered the European Pharmacopoeia. The future goal is to treat Chinese medicine most often. At least 300 Chinese herbal medicines used are included in the European Pharmacopoeia.
It is understood that the European Pharmacopoeia is the only guidance document for European drug quality testing. Based on the development momentum of traditional Chinese medicine in Europe, the European Pharmacopoeia established the Chinese Medicine Committee in 2008 to regulate the sales and use of Chinese herbal medicines and proprietary Chinese medicines in Europe.
At present, Chinese medicines that have entered the European Pharmacopoeia include 66 kinds of ginseng, dried tangerine peel, Atractylodes macrocephala, rhubarb, water safflower, Polygonum cuspidatum, and Sanqi, accounting for more than one-third of the 184 kinds of herbal medicines in the European Pharmacopoeia. Gerhard Franz said that every Chinese herbal medicine entering the European Pharmacopoeia requires rigorous testing and demonstration. If one of the 37 member states of the European Pharmacopoeia raises questions about a certain medicinal material, it will not be successful.
These 66 kinds of traditional Chinese medicines will have European-recognized standard specifications in terms of safety, quality and efficacy in the future, laying a foundation for the wider acceptance of Chinese medicines abroad, and also the first step for Chinese medicines to open export channels.